SCHEMBL5876798

SCHEMBL5876798

Cc1ccc(S(=O)(=O)n2nc(C(=O)O)c3c2CC(c2ccc(F)cc2)(c2ccc(F)cc2)C=C3)cc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.39
MAPK14 Q16539 1/20 0.36
ALDH1A1 P00352 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
STAT1 P42224 1/20 0.35
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
TAS2R14 Q9NYV8 1/20 0.35
GPR183 P32249 1/20 0.35
TP53 P04637 1/20 0.34
PKM P14618 1/20 0.34
KDM4E B2RXH2 1/20 0.34
APAF1 O14727 1/20 0.34
LMNA P02545 1/20 0.34
THRB P10828 1/20 0.34
MEN1 O00255 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5877142 0.97 CYP2C19 (0.38) KMT2AMAPK14ALDH1A1L3MBTL1STAT1
SCHEMBL5876186 0.91 CYP2C19 (0.42) KMT2AALDH1A1NR1H2NR1H3KDM4E
SCHEMBL5876034 0.90 NR1H2 (0.36) KMT2AMAPK14ALDH1A1NR1H2NR1H3
SCHEMBL5876786 0.89 KMT2A (0.40) KMT2AALDH1A1L3MBTL1STAT1NR1H2
SCHEMBL5876800 0.89 KMT2A (0.41) KMT2AALDH1A1L3MBTL1NR1H2NR1H3
SCHEMBL5876191 0.89 ALDH1A1 (0.39) KMT2AALDH1A1NR1H2NR1H3KDM4E
SCHEMBL5877376 0.89 MAPT (0.43) KMT2AALDH1A1PKMKDM4ELMNA
SCHEMBL5877639 0.88 KMT2A (0.36) KMT2AALDH1A1L3MBTL1NR1H2NR1H3
SCHEMBL5876231 0.87 CYP2C19 (0.39) KMT2AALDH1A1NR1H2NR1H3KDM4E
SCHEMBL5876634 0.86 ALDH1A1 (0.42) KMT2AALDH1A1NR1H2NR1H3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT KMT2A 2326/4885MAPK14 2756/4885ALDH1A1 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.